Thymidylate synthetase allelic imbalance in clear cell renal carcinoma

Davide Colavito, Giuseppe Cartei, Massimo Dal Bianco, Anna Stecca, Fable Zustovich, Maurizio Dalle Carbonare, Eugenio Ragazzi, Miriam Farina, Eva Colombrino, Alberta Leon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To investigate the allelic status of the thymidylate synthetase (TYMS) gene, located at chromosome band 18p11.32, in renal cell carcinoma (RCC). TYMS is a key target of the 5-fluorouracil (5-FU)-based class of drugs, frequently considered in combination therapies in advanced RCC. TYMS variants, such as the TYMS polymorphic 5′-untranslated region variable number tandem repeat sequence (VNTR), are under investigation to guide 5-FU treatment. Yet, no information is available with regard to changes in TYMS allele frequencies in RCC malignances. Methods: Blood and matched tumor samples were collected from 41 histological proven clear cell RCC affected patients (30 males, 11 females.). TYMS VNTR genotype was first determined in blood to identify heterozygotes employing PCR techniques. To evaluate for allelic imbalance, fragment analysis was performed both in blood and matched tumor DNA of the heterozygote patients. Microsatellite analysis, employing the markers D18S59 and D18S476 mapping, respectively, at the TYMS locus (18p11.32) and 1.5 Mb downstream of the TYMS gene sequence (18p11.31), was performed to confirm TYMS allelic imbalance in tumors. Results: Germ-line TYMS VNTR distribution was: 2R/2R (19.5%), TYMS 2R/3R (36.6%) and TYMS 3R/3R (43.9%). Allelic imbalance for the TYMS tandem repeat region was detected in 26.6% of the heterozygote patients. Microsatellite analysis confirmed the allelic imbalance detected by TYMS VNTR analysis and revealed that the overall frequence of allelic imbalance of chromosome band 18p11.32 was 35%, while the overall allelic imbalance of chromosome band 18p11.31 was 28%. Conclusions: By focusing on the TYMS polymorphic variants in renal cancer, we here provide evidence, to our knowledge, for the first time showing loss of 18p11.32 and 18p11.31 in renal cell carcinomas. As allelic imbalances involving TYMS locus may be an important variable affecting 5-FU responsiveness, this study may contribute to explain different responses of advanced RCC in combined chemotherapeutic regimens incorporating fluoropyridines.

Original languageEnglish
Pages (from-to)1195-1200
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number6
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Allelic Imbalance
Thymidylate Synthase
Renal Cell Carcinoma
Tandem Repeat Sequences
Minisatellite Repeats
Heterozygote
Chromosomes
Fluorouracil
Tumors
Blood
Microsatellite Repeats
Genes
Cells
Neoplasms

Keywords

  • Allelic imbalance
  • Microsatellite analysis
  • Renal cell carcinoma
  • Thymidylate synthetase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Colavito, D., Cartei, G., Dal Bianco, M., Stecca, A., Zustovich, F., Dalle Carbonare, M., ... Leon, A. (2009). Thymidylate synthetase allelic imbalance in clear cell renal carcinoma. Cancer Chemotherapy and Pharmacology, 64(6), 1195-1200. https://doi.org/10.1007/s00280-009-0986-9

Thymidylate synthetase allelic imbalance in clear cell renal carcinoma. / Colavito, Davide; Cartei, Giuseppe; Dal Bianco, Massimo; Stecca, Anna; Zustovich, Fable; Dalle Carbonare, Maurizio; Ragazzi, Eugenio; Farina, Miriam; Colombrino, Eva; Leon, Alberta.

In: Cancer Chemotherapy and Pharmacology, Vol. 64, No. 6, 11.2009, p. 1195-1200.

Research output: Contribution to journalArticle

Colavito, D, Cartei, G, Dal Bianco, M, Stecca, A, Zustovich, F, Dalle Carbonare, M, Ragazzi, E, Farina, M, Colombrino, E & Leon, A 2009, 'Thymidylate synthetase allelic imbalance in clear cell renal carcinoma', Cancer Chemotherapy and Pharmacology, vol. 64, no. 6, pp. 1195-1200. https://doi.org/10.1007/s00280-009-0986-9
Colavito D, Cartei G, Dal Bianco M, Stecca A, Zustovich F, Dalle Carbonare M et al. Thymidylate synthetase allelic imbalance in clear cell renal carcinoma. Cancer Chemotherapy and Pharmacology. 2009 Nov;64(6):1195-1200. https://doi.org/10.1007/s00280-009-0986-9
Colavito, Davide ; Cartei, Giuseppe ; Dal Bianco, Massimo ; Stecca, Anna ; Zustovich, Fable ; Dalle Carbonare, Maurizio ; Ragazzi, Eugenio ; Farina, Miriam ; Colombrino, Eva ; Leon, Alberta. / Thymidylate synthetase allelic imbalance in clear cell renal carcinoma. In: Cancer Chemotherapy and Pharmacology. 2009 ; Vol. 64, No. 6. pp. 1195-1200.
@article{482a7c83c7bf458cb1ce7232882492f5,
title = "Thymidylate synthetase allelic imbalance in clear cell renal carcinoma",
abstract = "Purpose: To investigate the allelic status of the thymidylate synthetase (TYMS) gene, located at chromosome band 18p11.32, in renal cell carcinoma (RCC). TYMS is a key target of the 5-fluorouracil (5-FU)-based class of drugs, frequently considered in combination therapies in advanced RCC. TYMS variants, such as the TYMS polymorphic 5′-untranslated region variable number tandem repeat sequence (VNTR), are under investigation to guide 5-FU treatment. Yet, no information is available with regard to changes in TYMS allele frequencies in RCC malignances. Methods: Blood and matched tumor samples were collected from 41 histological proven clear cell RCC affected patients (30 males, 11 females.). TYMS VNTR genotype was first determined in blood to identify heterozygotes employing PCR techniques. To evaluate for allelic imbalance, fragment analysis was performed both in blood and matched tumor DNA of the heterozygote patients. Microsatellite analysis, employing the markers D18S59 and D18S476 mapping, respectively, at the TYMS locus (18p11.32) and 1.5 Mb downstream of the TYMS gene sequence (18p11.31), was performed to confirm TYMS allelic imbalance in tumors. Results: Germ-line TYMS VNTR distribution was: 2R/2R (19.5{\%}), TYMS 2R/3R (36.6{\%}) and TYMS 3R/3R (43.9{\%}). Allelic imbalance for the TYMS tandem repeat region was detected in 26.6{\%} of the heterozygote patients. Microsatellite analysis confirmed the allelic imbalance detected by TYMS VNTR analysis and revealed that the overall frequence of allelic imbalance of chromosome band 18p11.32 was 35{\%}, while the overall allelic imbalance of chromosome band 18p11.31 was 28{\%}. Conclusions: By focusing on the TYMS polymorphic variants in renal cancer, we here provide evidence, to our knowledge, for the first time showing loss of 18p11.32 and 18p11.31 in renal cell carcinomas. As allelic imbalances involving TYMS locus may be an important variable affecting 5-FU responsiveness, this study may contribute to explain different responses of advanced RCC in combined chemotherapeutic regimens incorporating fluoropyridines.",
keywords = "Allelic imbalance, Microsatellite analysis, Renal cell carcinoma, Thymidylate synthetase",
author = "Davide Colavito and Giuseppe Cartei and {Dal Bianco}, Massimo and Anna Stecca and Fable Zustovich and {Dalle Carbonare}, Maurizio and Eugenio Ragazzi and Miriam Farina and Eva Colombrino and Alberta Leon",
year = "2009",
month = "11",
doi = "10.1007/s00280-009-0986-9",
language = "English",
volume = "64",
pages = "1195--1200",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Thymidylate synthetase allelic imbalance in clear cell renal carcinoma

AU - Colavito, Davide

AU - Cartei, Giuseppe

AU - Dal Bianco, Massimo

AU - Stecca, Anna

AU - Zustovich, Fable

AU - Dalle Carbonare, Maurizio

AU - Ragazzi, Eugenio

AU - Farina, Miriam

AU - Colombrino, Eva

AU - Leon, Alberta

PY - 2009/11

Y1 - 2009/11

N2 - Purpose: To investigate the allelic status of the thymidylate synthetase (TYMS) gene, located at chromosome band 18p11.32, in renal cell carcinoma (RCC). TYMS is a key target of the 5-fluorouracil (5-FU)-based class of drugs, frequently considered in combination therapies in advanced RCC. TYMS variants, such as the TYMS polymorphic 5′-untranslated region variable number tandem repeat sequence (VNTR), are under investigation to guide 5-FU treatment. Yet, no information is available with regard to changes in TYMS allele frequencies in RCC malignances. Methods: Blood and matched tumor samples were collected from 41 histological proven clear cell RCC affected patients (30 males, 11 females.). TYMS VNTR genotype was first determined in blood to identify heterozygotes employing PCR techniques. To evaluate for allelic imbalance, fragment analysis was performed both in blood and matched tumor DNA of the heterozygote patients. Microsatellite analysis, employing the markers D18S59 and D18S476 mapping, respectively, at the TYMS locus (18p11.32) and 1.5 Mb downstream of the TYMS gene sequence (18p11.31), was performed to confirm TYMS allelic imbalance in tumors. Results: Germ-line TYMS VNTR distribution was: 2R/2R (19.5%), TYMS 2R/3R (36.6%) and TYMS 3R/3R (43.9%). Allelic imbalance for the TYMS tandem repeat region was detected in 26.6% of the heterozygote patients. Microsatellite analysis confirmed the allelic imbalance detected by TYMS VNTR analysis and revealed that the overall frequence of allelic imbalance of chromosome band 18p11.32 was 35%, while the overall allelic imbalance of chromosome band 18p11.31 was 28%. Conclusions: By focusing on the TYMS polymorphic variants in renal cancer, we here provide evidence, to our knowledge, for the first time showing loss of 18p11.32 and 18p11.31 in renal cell carcinomas. As allelic imbalances involving TYMS locus may be an important variable affecting 5-FU responsiveness, this study may contribute to explain different responses of advanced RCC in combined chemotherapeutic regimens incorporating fluoropyridines.

AB - Purpose: To investigate the allelic status of the thymidylate synthetase (TYMS) gene, located at chromosome band 18p11.32, in renal cell carcinoma (RCC). TYMS is a key target of the 5-fluorouracil (5-FU)-based class of drugs, frequently considered in combination therapies in advanced RCC. TYMS variants, such as the TYMS polymorphic 5′-untranslated region variable number tandem repeat sequence (VNTR), are under investigation to guide 5-FU treatment. Yet, no information is available with regard to changes in TYMS allele frequencies in RCC malignances. Methods: Blood and matched tumor samples were collected from 41 histological proven clear cell RCC affected patients (30 males, 11 females.). TYMS VNTR genotype was first determined in blood to identify heterozygotes employing PCR techniques. To evaluate for allelic imbalance, fragment analysis was performed both in blood and matched tumor DNA of the heterozygote patients. Microsatellite analysis, employing the markers D18S59 and D18S476 mapping, respectively, at the TYMS locus (18p11.32) and 1.5 Mb downstream of the TYMS gene sequence (18p11.31), was performed to confirm TYMS allelic imbalance in tumors. Results: Germ-line TYMS VNTR distribution was: 2R/2R (19.5%), TYMS 2R/3R (36.6%) and TYMS 3R/3R (43.9%). Allelic imbalance for the TYMS tandem repeat region was detected in 26.6% of the heterozygote patients. Microsatellite analysis confirmed the allelic imbalance detected by TYMS VNTR analysis and revealed that the overall frequence of allelic imbalance of chromosome band 18p11.32 was 35%, while the overall allelic imbalance of chromosome band 18p11.31 was 28%. Conclusions: By focusing on the TYMS polymorphic variants in renal cancer, we here provide evidence, to our knowledge, for the first time showing loss of 18p11.32 and 18p11.31 in renal cell carcinomas. As allelic imbalances involving TYMS locus may be an important variable affecting 5-FU responsiveness, this study may contribute to explain different responses of advanced RCC in combined chemotherapeutic regimens incorporating fluoropyridines.

KW - Allelic imbalance

KW - Microsatellite analysis

KW - Renal cell carcinoma

KW - Thymidylate synthetase

UR - http://www.scopus.com/inward/record.url?scp=69049117206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049117206&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-0986-9

DO - 10.1007/s00280-009-0986-9

M3 - Article

VL - 64

SP - 1195

EP - 1200

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -